The New Zealand Parkinson's progression programme
Michael R MacAskill1,2, Toni L Pitcher1,2, Tracy R Melzer1,2,3
1New Zealand Brain Research Institute, Christchurch, New Zealand.
Journal of the Royal Society of New Zealand
|October 23, 2024
Summary
The New Zealand Parkinson's Progression Programme (NZP3) has studied cognitive impairment in Parkinson's disease for 14 years. It identified biomarkers and established criteria for mild cognitive impairment (MCI) in Parkinson's patients.
Area of Science:
- Neurology
- Neuroscience
- Biomarker Research
Background:
- The New Zealand Parkinson's Progression Programme (NZP3) has been running for 14 years.
- It involves 354 individuals with Parkinson's disease and 89 healthy controls.
- Research focuses on cognitive impairment and its early detection in Parkinson's disease.
Purpose of the Study:
- To characterize cognitive impairment in Parkinson's disease.
- To identify biomarkers for predicting future cognitive decline.
- To establish standardized criteria for mild cognitive impairment (MCI) in Parkinson's.
Main Methods:
- Longitudinal study design over 14 years.
- Participant recruitment of individuals with Parkinson's disease and healthy controls.
- Utilizing brain imaging (MRI, PET), genetic analysis, fluid biomarkers, eye movement, speech analysis, and quantitative electroencephalography (EEG).
Main Results:
- Significant contributions to understanding mild cognitive impairment (MCI) in Parkinson's disease.
- Development and validation of standardized criteria for MCI.
- Established associations between brain pathology (via MRI/PET) and cognitive decline.
Conclusions:
- The NZP3 programme has advanced the understanding and diagnosis of cognitive impairment in Parkinson's disease.
- It serves as a platform for diverse research, including epidemiology and caregiver burden.
- The programme has fostered a skilled research community and produced numerous publications and theses.
Related Concept Videos
01:15Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
01:24Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227